目的 探討前列欣膠囊聯(lián)合鹽酸特拉唑嗪膠囊治療前列腺增生癥的臨床療效。方法 選取2018年5月-2020年5月在新鄉(xiāng)市中心醫(yī)院治療的前列腺增生癥患者242例，根據(jù)用藥的差別分為對(duì)照組（121例）和治療組（121例）。對(duì)照組口服鹽酸特拉唑嗪膠囊，2 mg/次，1次/d；治療組在對(duì)照組基礎(chǔ)上口服前列欣膠囊，3.0 g/次，3次/d。兩組患者均治療30 d。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者前列腺體積、殘余尿量（PVR）、最大尿流率（Q_max），IPSS、VSS、QOL和USPSS評(píng)分，及血清胰島素樣生長(zhǎng)因子-1（IGF-1）、B細(xì)胞淋巴瘤/白血病-2（Bcl-2）、脂蛋白相關(guān)磷脂酶A2（LP-PLA2）和白細(xì)胞介素-17（IL-17）水平。結(jié)果 治療后，對(duì)照組臨床總有效率為80.49%，顯著低于治療組的97.56%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者前列腺體積、PVR均顯著降低（P<0.05），而Q_max均顯著升高（P<0.05），且治療組明顯好于對(duì)照組（P<0.05）。治療后，兩組患者IPSS評(píng)分、VSS評(píng)分、QOL評(píng)分、USPSS評(píng)分均顯著下降（P<0.05），且治療組下降最為明顯（P<0.05）。治療后，兩組患者血清IGF-1、Bcl-2、Lp-PLA2、IL-17水平均明顯降低（P<0.05），且治療組明顯低于對(duì)照組（P<0.05）。結(jié)論 前列欣膠囊聯(lián)合鹽酸特拉唑嗪膠囊治療前列腺增生癥可有效改善患者臨床癥狀，降低血清IGF-1、Bcl-2、Lp-PLA2、IL-17水平，提高患者生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Qianliexin Capsules combined with terazosin in treatment of benign prostatic hyperplasia. Methods Patients (242 cases) with benign prostatic hyperplasia in Xinxiang Central Hospital from May 2018 to May 2020 were divided into control (121 cases) and treatment (121 cases) groups based on different treatments. Patients in the control group were po administered with Terazosin Hydrochloride Capsules, 2 mg/time, once daily. Patients in the treatment group were po administered with Qianliexin Capsules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacy was evaluated, and the prostate volume, PVR, Q_max, and the scores of IPSS, VSS, QOL and USPSS, and the serum levels of IGF-1, Bcl-2, LP-PLA2 and IL-17 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.49%, which was significantly lower than 97.56% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the prostate volume and PVR in two groups were significantly decreased (P<0.05), but the Q_max level in two groups was significantly increased (P<0.05), and the indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the scores of IPSS, VSS, QOL and USPSS in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum levels of IGF-1, Bcl-2, LP-PLA2, and IL-17 in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Qianliexin Capsules combined with terazosin in treatment of benign prostatic hyperplasia can effectively improve the clinical symptoms, reduce the serum levels of IGF-1, Bcl-2, Lp-PLA2, and IL-17, and improve the quality of life of patients, which has a certain clinical application value.

R983

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（LHGJ20191317）